Home Brand News Aurobindo Pharma’s subsidiary Acrotech Biopharma to acquire portfolio of seven marketed oncology...

Aurobindo Pharma’s subsidiary Acrotech Biopharma to acquire portfolio of seven marketed oncology injectable products

290
0

Acquisition for an upfront purchase price of $160 million in cash plus up to $140 million on achieving
regulatory and sales-based milestones
 Acquired portfolio includes seven branded oncology inject-able products which are currently
being marketed. The acquisition also brings-in an experienced branded commercial
infrastructure in the US
 The portfolio is expected to generate a revenue of around $100 million for the first 12 months
after completion of the transaction for Aurobindo
 Transaction will be EPS accretive from first full year of ownership
Hyderabad, India, 17th January 2019: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA)
(“Aurobindo”), announces the signing of a definitive agreement to acquire a portfolio of seven branded
oncology injectable products from Spectrum pharmaceuticals Inc. The acquisition also brings-in an
experienced branded commercial infrastructure in the US.
Acrotech Bio-pharma LLC (“Acrotech”), a wholly-owned subsidiary of Aurobindo Pharma USA Inc., which
in turn a wholly-owned subsidiary of Aurobindo Pharma Limited, will be acquiring the portfolio on a
debt free and cash free basis. This acquisition is in line with our strategy to commercialize innovative
proprietary medications.
The acquisition will help Aurobindo Group to enter the branded oncology market with a range of
products which are well recognized by the oncology community. Aurobindo Group will also acquire a
well-established and experienced branded commercial infrastructure to continue commercializing these
brands.
Commenting on the transaction, Dr. Ashish Anvekar, President of Acrotech, said: “We are excited to
jump-start our mission of helping cancer patients across the globe by delivering clinically differentiated
medications and leveraging strategic partnerships. We look forward to welcome an experienced team of
employees from Spectrum who are essential to our mission.”
Commenting on the transaction, Mr. N. Govindarajan, Managing Director of Aurobindo, said:
“The acquisition announced today creates an ideal launch pad for Acrotech, and establishes our presence
in the branded market, which is in line with our strategy to grow and diversify our business in the US.”
Mr. Govindarajan added, “We look forward to deliver the benefits of this transaction to all our
stakeholders including employees, patients, customers and healthcare providers across the US. “

LEAVE A REPLY

Please enter your comment!
Please enter your name here